Literature DB >> 17443226

Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.

J H Klusmann, D Reinhardt, H Hasle, G J Kaspers, U Creutzig, K Hahlen, M M van den Heuvel-Eibrink, C M Zwaan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17443226     DOI： 10.1038/sj.leu.2404694

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

Review 2.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

3.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

Authors:  Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

4.  Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.

Authors:  Ashley P Ng; Yifang Hu; Donald Metcalf; Craig D Hyland; Helen Ierino; Belinda Phipson; Di Wu; Tracey M Baldwin; Maria Kauppi; Hiu Kiu; Ladina Di Rago; Douglas J Hilton; Gordon K Smyth; Warren S Alexander
Journal:  PLoS Genet       Date:  2015-05-14       Impact factor: 5.917

Review 5.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

6.  GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.

Authors:  A Maroz; L Stachorski; S Emmrich; K Reinhardt; J Xu; Z Shao; S Käbler; T Dertmann; J Hitzler; I Roberts; P Vyas; G Juban; C Hennig; G Hansen; Z Li; S Orkin; D Reinhardt; J-H Klusmann
Journal:  Leukemia       Date:  2013-12-13       Impact factor: 11.528

Review 7.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 8.  Down syndrome--recent progress and future prospects.

Authors:  Frances K Wiseman; Kate A Alford; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

9.  Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.

Authors:  M V Stankov; M El Khatib; B Kumar Thakur; K Heitmann; D Panayotova-Dimitrova; J Schoening; J P Bourquin; N Schweitzer; M Leverkus; K Welte; D Reinhardt; Z Li; S H Orkin; G M N Behrens; J H Klusmann
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

10.  Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.

Authors:  Aarti Ruparelia; Frances Wiseman; Olivia Sheppard; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Biomed Res       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.